Dulaglutide (GLP-1 agonist)

metabolic glycemic

Approved medicine for another condition in 8 of 9 markets tracked; in clinical trials in 1.

Evidence so far is from 1 human trial with no pre-planned main endpoint and animal studies.

In people: 1 trial (9,901 people, 5 years). Doses studied: 1.5 mg.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (2)

T8 Riddle 2021 Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial doi:10.1210/clinem/dgab065
T3 Khin 2021 Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice doi:10.18632/aging.203546